4Sui LP,Li R D,Song B,et al.Characterization of two degradationproducts of Azilsartan formed during the micronization process anddevelopment of a method to control the degradation[J].J.Chin.Pharm.Sci.,2014,23(5),302-305.
5Surbhi M,Ravi P.S,Rajkamal P,et al.LC and LC-MS/TOFstudies on stress degradation behaviour of candesartan cilexetil[J].J.Pharm.Biome.Anal.,2010,52:345-354.
6Bhanu R,Brajesh A S,Ganesh M,et al.Investigation and structuralelucidation of a process related impurity in candesartan cilexetil by LC/ESI-ITMS and NMR[J].J,Pharm.Biome.Anal.,2011,56:256-263.
7Orbe J,Fernandez L,Rodriguez J A,et al.Different expression of MMPs/TIMP-1 in human atherosclerotic lesions.Relation to plaque features and vascular bed[J].Atherosclerosis,2003,170(2):269-276.
8Sada T,Mizuno M.Pharmacological profiles and clinical effects of olmesartan medoxomil,a novel angiotensin II receptor blocker[J].Nihon Yakurigaku Zasshi,2004,124(4):257-269.
9Lastra G,Santos FR,Hooshmand P,et al.The Novel Angiotensin II Receptor Blocker Azilsartan Medoxomil Ameliorates Insulin Resistance Induced by Chronic Angiotensin II Treatment in Rat Skeletal Muscle[J].Cardiorenal Med,2013,3(2):154-164.
10Amaral SL,Michelini LC.Effect of gender on training-induced vascular remodeling in SHR[J].Braz J Med Biol Res,2011,44(9):814-826.
